Search company, investor...

Predict your next investment

Gurnet Point Capital company logo
Private Equity
gurnetpointcapital.com

Investments

16

Portfolio Exits

2

Partners & Customers

1

Service Providers

1

About Gurnet Point Capital

Gurnet Point Capital is a private equity firm that invests in de-risked life sciences companies. It provides funds across all stages of product development including clinical trial design and execution, drug development, regulatory affairs, toxicology, and other areas related to developing early-stage medicines and devices. The company was founded in 2015 and is based in Cambridge, Massachusetts.

Headquarters Location

55 Cambridge Parkway Suite 401

Cambridge, Massachusetts, 02142,

United States

617-588-4900

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Expert Collections containing Gurnet Point Capital

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Gurnet Point Capital in 1 Expert Collection, including Vitamin & Supplement Startups.

V

Vitamin & Supplement Startups

237 items

Latest Gurnet Point Capital News

CORIUM INNOVATIONS TO SHOWCASE ITS PATENTED DRUG DELIVERY TECHNOLOGIES AT CPHI

Oct 18, 2023

News provided by Share this article Leadership in attendance in Barcelona ready to talk to potential partners and collaborators GRAND RAPIDS, Mich., Oct. 18, 2023 /PRNewswire/ -- Corium Innovations, Inc.  , a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, announced today that it will be featuring its industry leading transdermal, microarray and oral thin film  technologies  at booth 80N27 during the upcoming CPHI Barcelona 2023, to be held October 24-26 in Barcelona, Spain. With 25 years of making and leveraging groundbreaking transdermal delivery systems since it was founded, Corium Innovations maintains fully integrated research & development capabilities along with annual manufacturing capacity of more than 200 million transdermal patches/films at its 200,000 square foot GMP facility in Grand Rapids, Michigan. Corium Innovations brings the best of its proprietary transdermal and transmucosal delivery platforms to different patient and consumer groups in customary or challenging usage situations. Featuring industry leading transdermal, microarray and oral thin film technologies during CPHI Barcelona 2023 "Our passion for continually cracking the code in drug delivery is proven and enables us to deliver more than medicine. It enables us to deliver healthier outcomes," said Dr. Mark Sirgo, Chief Executive Officer at Corium Innovations. "Our teams of scientists and engineers never stop finding ways to create solutions for partners by adapting our tunable technologies for a vast range of therapies, including biologics. We keep pushing forward to develop high-value brands and complex generic products. Both for the partners we work for today – and for those in the future." Nearly a quarter-century ago, led by Dr. Gary Cleary, Adrian Faasse and their teams set out to use cutting-edge science and engineering to create a bold new world of drug-delivery technologies. Since then, the Corium Innovations team has published 35 scientific papers and more than 90 patents covering a wide range of scientific research in drug delivery, including applications for transdermal, polymer and permeation enhancement technologies. Corium Innovations' proprietary Corplex® transdermal innovation platform breaks new ground in drug delivery with a proprietary mix of adhesives, polymers and liners that can be adjusted for almost any use situation. From teeth whitening strips, to the first and only 7-day continuous treatment patch for Alzheimer's disease, Corplex is helping millions of people get the help and benefits they are seeking in a way that works better for their lives. About Corium Innovations Headquartered in Grand Rapids, Michigan, Corium Innovations is a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies. With a track record spanning nearly 30 years, Corium Innovations offers end-to-end solutions to its partners, from formulation and product development work, through commercial-scale manufacturing and packaging. The company's success is enabled by its state-of-the-art facilities, highly tenured operational leadership, and its proprietary proven drug delivery technology CORPLEX®. For more information, visit  https://www.coriuminv.com . About Gurnet Point Capital Gurnet Point Capital is a leading healthcare fund that invests in de-risked life sciences companies. Gurnet Point primarily focuses on businesses that have high growth potential in the late product development and commercialization stages of their evolution. These companies become partners not just because of their capacity to generate economic value, but also because of their potential to deliver social impact. Gurnet Point's team of highly experienced industry executives works closely with its portfolio companies, with an active approach driving operational transformation and outsized returns. www.gurnetpointcapital.com/ About Webster Equity Partners Founded in 2003, Webster is a private equity firm that focuses on high impact growth strategies that seek to deliver optimal outcomes for our investors, portfolio companies and the communities that we serve. Our mission is to deliver superior returns to our partners through the investment in and development of purpose driven patient-centric healthcare organizations dedicated to providing best of class clinical care and service to their patients. https://websterequitypartners.com/ SOURCE Corium Innovations, Inc.

Gurnet Point Capital Investments

16 Investments

Gurnet Point Capital has made 16 investments. Their latest investment was in Naveris as part of their Series A - II on September 9, 2022.

CBI Logo

Gurnet Point Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/19/2022

Series A - II

Naveris

$33.4M

No

5

6/22/2022

Series D

Alladapt Immunotherapeutics

$119M

No

8

5/23/2022

Series A

Fairtility

$15M

Yes

Nacre Capital, and Undisclosed Investors

1

8/11/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

4/16/2020

Series A - III

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/19/2022

6/22/2022

5/23/2022

8/11/2021

4/16/2020

Round

Series A - II

Series D

Series A

Series B

Series A - III

Company

Naveris

Alladapt Immunotherapeutics

Fairtility

Subscribe to see more

Subscribe to see more

Amount

$33.4M

$119M

$15M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Nacre Capital, and Undisclosed Investors

Sources

5

8

1

10

10

Gurnet Point Capital Portfolio Exits

2 Portfolio Exits

Gurnet Point Capital has 2 portfolio exits. Their latest portfolio exit was Zikani Therapeutics on April 01, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/1/2021

Acquired

$99M

3

2/3/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/1/2021

2/3/2021

Exit

Acquired

Acquired

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Sources

3

10

Gurnet Point Capital Acquisitions

4 Acquisitions

Gurnet Point Capital acquired 4 companies. Their latest acquisition was Paratek Pharmaceuticals on September 20, 2023.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/20/2023

Debt

$99M

$129.3M

Take Private

10

8/15/2022

Series B

Subscribe to see more

$99M

$99M

Subscribe to see more

10

11/27/2018

Series C

Subscribe to see more

$99M

$99M

Subscribe to see more

10

7/24/2017

Other

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

9/20/2023

8/15/2022

11/27/2018

7/24/2017

Investment Stage

Debt

Series B

Series C

Other

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Total Funding

$129.3M

$99M

$99M

$99M

Note

Take Private

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

10

10

10

10

Gurnet Point Capital Partners & Customers

1 Partners and customers

Gurnet Point Capital has 1 strategic partners and customers. Gurnet Point Capital recently partnered with Zevra Therapeutics on April 4, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

4/8/2021

Licensor

United States

KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS™

`` The last few weeks since AZSTARYS was approved have been an exciting and busy time as we have worked with our partners at Gurnet Point Capital and Corium to re-evaluate the commercial potential of AZSTARYS based on the final approved label , and negotiated adjustments to the economics of our License Agreement to optimize investment in the commercial launch and , ultimately , long-term value creation .

1

Date

4/8/2021

Type

Licensor

Business Partner

Country

United States

News Snippet

KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS™

`` The last few weeks since AZSTARYS was approved have been an exciting and busy time as we have worked with our partners at Gurnet Point Capital and Corium to re-evaluate the commercial potential of AZSTARYS based on the final approved label , and negotiated adjustments to the economics of our License Agreement to optimize investment in the commercial launch and , ultimately , long-term value creation .

Sources

1

Gurnet Point Capital Service Providers

1 Service Provider

Gurnet Point Capital has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Take Private

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Take Private

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Gurnet Point Capital Team

4 Team Members

Gurnet Point Capital has 4 team members, including current Chief Financial Officer, Gretchen McCarey.

Name

Work History

Title

Status

Gretchen McCarey

Waypoint Capital, Accomplice, Atlas Venture, Globespan Capital Partners, Sparta Group, Citizens Capital, New England Investment and Retirement Group, and Deloitte

Chief Financial Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Gretchen McCarey

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Waypoint Capital, Accomplice, Atlas Venture, Globespan Capital Partners, Sparta Group, Citizens Capital, New England Investment and Retirement Group, and Deloitte

Title

Chief Financial Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.